Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study

Lancet Neurology

Volumn 5, Issue 8, 2006, Pages 655-660

  van Oijen, Marieke ^a   Hofman, Albert ^a   Soares, Holly D ^b   Koudstaal, Peter J ^a   Breteler, Monique MB ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; DEMENTIA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; MENTAL HEALTH; METHODOLOGY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; RISK; STATISTICS; TIME;

AGED; AMYLOID BETA-PROTEIN; COHORT STUDIES; CONFIDENCE INTERVALS; DEMENTIA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PROPORTIONAL HAZARDS MODELS; RISK; TIME FACTORS;

EID: 33745959062     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(06)70501-4     Document Type: Article

References (30)

1. Selkoe D. Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol 53 (1994) 438-447
2. Selkoe D. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 17 (1994) 489-517
3. Younkin S. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann Neurol 37 (1995) 287-288
4. Iwatsubo T., Mann D., Odaka A., Suzuki N., and Ihara Y. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann Neurol 37 (1995) 294-299
5. Deane R., Du Yan S., Submamaryan R., et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9 (2003) 907-913
6. DeMattos R., Bales K., Cummins D., Paul S., and Holtzman D. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295 (2002) 2264-2267
7. Chen M., Inestrosa N., Ross G., and Fernandez H. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 213 (1995) 96-103
8. van Dijk E., Prins N., Vermeer S., et al. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann Neurol 55 (2004) 570-575
9. Mayeux R., Honig L., Tang M., et al. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
10. Scheuner D., Eckman C., Jensen M., et al. Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2 (1996) 864-870
11. Schupf N., Patel B., Silverman W., et al. Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett 301 (2001) 199-203
12. Younkin S. The role of A beta 42 in Alzheimer's disease. J Physiol Paris 92 (1998) 289-292
13. Graff-Radford N. Analysis of plasma Aβ42 as a premorbid marker for late onset Alzheimer's disease. Neurobiol Aging 25 (2004) 354
14. Pomara N., Willoughby L., Sidtis J., and Mehta P. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am J Geriatr Psychiatry 13 (2005) 914-917
15. Kawarabayashi T., Younkin L., Saido T., Shoji M., Ashe K., and Younkin S. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21 (2001) 372-381
16. Hofman A., Grobbee D., de Jong P., and van den Ouweland F. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 7 (1991) 403-422
17. Barlow W. Robust variance estimation for the case-cohort design. Biometrics 50 (1994) 1064-1072
18. Barlow W., Ichikawa L., Rosner D., and Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 52 (1999) 1165-1172
19. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984) 939-944
20. Roman G., Tatemichi T., Erkinjuntti T., et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 (1993) 250-260
21. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 357 (2001) 169-175
22. Mehta P., Pirttila T., Mehta S., Sersen E., Aisen P., and Wisniewski H. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57 (2000) 100-105
23. Iwatsubo T. Amyloid beta protein in plasma as a diagnostic marker for Alzheimer's disease. Neurobiol Aging 19 (1998) 161-163
24. Assini A., Cammarata S., Vitali A., et al. Plasma levels of amyloid beta-protein 42 are increased in women with mild cognitive impairment. Neurology 63 (2004) 828-831
25. Ghersi-Egea J., Gorevic P., Ghiso J., Frangione B., Patlak C., and Fenstermacher J. Fate of cerebrospinal fluid-borne amyloid beta-peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries. J Neurochem 67 (1996) 880-883
26. Motter R., Vigo-Pelfrey C., Kholodenko D., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 38 (1995) 643-648
27. Skovronsky D., Lee V., and Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem 276 (2001) 17036-17043
28. Thomas T., Thomas G., McLendon C., Sutton T., and Mullan M. beta-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 380 (1996) 168-171
29. Gurol M., Irizarry M., Smith E., et al. Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 66 (2006) 23-29
30. Vermeer S., Prins N., den Heijer T., Hofman A., Koudstaal P., and Breteler M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348 (2003) 1215-1222